Allograft vasculopathy is the leading cause of late allograft loss following solid organ transplantation. Ischemia reperfusion injury and donor-specific antibody-induced complement activation confer heightened risk for allograft vasculopathy via numerous innate immune mechanisms, including MyD88, high-mobility group box 1 (HMGB1), and complement-induced noncanonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling.
INTRODUCTION
Allograft vasculopathy is a highly prevalent vaso-occlusive condition that affects up to 51% of patients 10 years after transplant [1] . In allograft vasculopathy, neointimal and less commonly thrombotic lesions form in large and small-caliber vessels of the transplanted graft, leading to ischemic complications and allograft loss. In the setting of heart transplantation, where allograft vasculopathy is most widely studied and is referred to as cardiac allograft vasculopathy or cardiac allograft vasculopathy (CAV), allograft vasculopathy lesions affect the epicardial coronary and intramyocardial microvessels [2] and is recognized as the leading cause of graft loss after 1-year postheart transplantation. Ischemia reperfusion injury (IRI) and development of donor-specific antibodies (DSA) are both strong, independent risk factors for the development of allograft vasculopathy.
Allograft vasculopathy is a fundamentally distinct entity from coronary artery disease. Given its unique pathophysiological underpinnings involving alloimmune T-cell activation, allograft vasculopathy is clinically refractory to many repositioned agents intended for treating coronary artery disease [3] . Moreover, contemporary immunosuppressive regimens to halt alloimmune adaptive responses have yielded only incremental or no therapeutic benefit regarding secondary or tertiary prevention [4, 5] . Future agents specifically designed for treating allograft vasculopathy are required, and for the rational design of such therapies an improved understanding of the mechanisms underlying allograft vasculopathy is urgently needed. Here, we review the role of innate immune signaling molecules and pathways, including high-mobility group box (HMGB), MyD88, and complementinduced noncanonical NF-kB, in the development of allograft vasculopathy.
MYD88: A CENTRAL PATHWAY ENHANCING CHRONIC ALLOGRAFT REJECTION
MyD88 is a signal adaptor protein that is downstream of all the Toll-like receptors (TLRs), except TLR3 and also IL-1 and IL-18. TLRs are key innate immune receptors that are expressed on stromal and hematopoietic cells and activated by both microbial and nonmicrobial activators [6, 7] . MyD88 has been established to enhance acute allograft rejection and break transplant tolerance [8] [9] [10] . In humans, patients with low expression of MyD88 in peripheral blood mononuclear cells exhibit a significant increase in operational transplant tolerance as compared with renal transplant recipients with evidence of chronic rejection [11] . Mechanistically, MyD88 signaling in an experimental model of kidney transplantation abrogates spontaneous transplant tolerance [12] . MyD88 impaired the expansion of regulatory T cells and increased antidonor IL-17 immune responses [12, 13] . Interestingly, the authors of this study recently reported that IL-17 enhanced both acute and chronic allograft rejection in a spontaneous model of murine renal allograft acceptance [14] . The MyD88 expressing cells that mediate allograft vasculopathy have not been determined. Prior studies have indicated that NK cells and macrophages may promote allograft vasculopathy and represent potential possibilities [15, 16] .
In a major histocompatibility complex (MHC) class II mismatched murine cardiac allograft model, deficiency of MyD88 in the recipient enhanced cardiac allograft survival with reduced evidence of allograft vasculopathy [17 && ]. This study also found that there were increased numbers of Trem-1 þ immune cells within human heart transplant biopsy specimens with evidence of acute graft rejection [17 && ]. Triggering receptor on myeloid receptor 1 (Trem-1) is an immunoglobulin superfamily member that is expressed on a variety of innate immune cells, including dendritic cells, macrophages and neutrophils acts as an amplifying signal for MyD88 [18] . Importantly, pharmacological inhibition of Trem-1 enhanced cardiac allograft survival with reduced allograft vasculopathy development in the murine MHC class II mismatched model [17 && ]. Trem1 inhibition also reduced T-cell allograft infiltration and reduced antidonor IFN-g T-cell responses within the spleen of cardiac allograft recipients [17 && ,18] . Thus, this study defines a role for Trem-1 as MyD88 amplification signal that enhances allograft vasculopathy.
IRI leads to cellular necrosis and induces sterile inflammation [19] . During cellular necrosis, substances are released that are typically not sensed by the innate immune system [18, 19] . HMGB1 is a nuclear protein that enhances gene transcription [20] . It has been shown to activate TLR 4 and TLR9, TLRs upstream of MyD88 [21] [22] . Prior studies have found a role for HMGB1 in acute allograft rejection as well as cardiac, renal, and hepatic IRI [23] [24] [25] [26] [27] . Recently, in a MHC class II mismatched cardiac allograft model, pharmacological blockade of HMGB1 reduced allograft vasculopathy and was associated with reduced numbers of graft infiltrating T helper 1 (Th1) and Th17 producing T cells [28 && ]. Importantly, blockade of HMGB1 correlated with reduced numbers of inflammatory monocytes and macrophages within the spleen of cardiac allograft recipients [28 && ]. Although not focused on allograft vasculopathy, a recent study found that blockade of HMGB1 reduced vascular rejection and antidonor B cells in a murine xenograft model (rat grafts into murine recipients) [29] . Overall, these studies indicate that HMGB1 enhances vascular disease and allograft vasculopathy in mice.
Lung allografts are also susceptible to chronic allograft rejection. Chronic rejection after lung transplantation is termed bronchiolitis obliterans syndrome (BOS). Prior human studies have implicated TLR4 in the development of BOS [30] . A recent study has found that the level or hyaluronan a glycosaminoglycan that activates MyD88 [31] , is increased after lung transplantation in humans and correlates with the development of BOS [32 && ]. Interestingly, in the same study the investigators found that administration of hyaluronan broke lung transplant tolerance in mice via a
KEY POINTS
Innate immunity and complement activation enhance allograft vasculopathy.
MyD88 promotes allograft vasculopathy in part via activation of HMGB1 released after graft IRI.
Noncanonical NF-kB is a novel complement effector pathway that requires an endosome-based signaling mechanism to elicit endothelial cell activation to promote allograft vasculopathy.
MyD88-dependent process [30,32 && ]. Other activators of innate immunity, specifically the S100 proteins or calgranulins, which can induce vascular inflammation [33] , have also been found in the bronchoalveolar lavage of lung transplant recipients that exhibited signs of BOS [34 & ]. A recent experimental study found that calgranulins were upregulated within cardiac transplants [35] but whether calgranulins associate with allograft vasculopathy after cardiac transplantation is yet to be studied.
COMPLEMENT ACTIVATION AS A LINK BETWEEN ISCHEMIA REPERFUSION INJURY AND ALLOGRAFT VASCULOPATHY
Activation of the complement cascade occurs in response to IRI or DSA binding to human leukocyte antigen (HLA) molecules on endothelial cells, the sites where allograft vasculopathy lesions occur. Interestingly, a recent murine study demonstrated severe renal IRI enhanced humoral immunity [36 && ]. Specifically, bilateral, but not unilateral renal IRI in mice, enhanced the production of antigen-specific IgG 1 levels [36 && ]. Furthermore, this study demonstrated that complement activation was critical for the amplified antigen-specific humoral response induced by renal IRI as mice that are deficient in factor B, a critical component of the alternate complement cascade, exhibited an abrogated humoral response [36 && ]. Although this study employed a native renal IRI model and not an organ transplant model, it implies the IRI after graft implantation enhances the generation of DSA, which could enhance complement activation to promote allograft vasculopathy.
DONOR-SPECIFIC ANTIBODY AND TERMINAL COMPLEMENT INDUCE INFLAMMATORY SIGNALING IN THE GRAFT VASCULATURE, A POTENTIAL CONNECTION TO ALLOGRAFT VASCULOPATHY
DSA binding to HLA I [37] and II [38] molecules on the graft vasculature potentiates the proliferative and migratory capacities of endothelial cell and promotes allograft vasculopathy in a manner that involves activation of Akt, a serine/threonine kinase regulating protein translation and metabolism [39] . DSA biding to HLA class I molecules via integrin b4 activates Akt [40] , which potentiates endothelial cell proliferation and migration. Underscoring its clinical significance, activated Akt phospho-targets, including S6 kinase and S6 ribosomal protein, are significantly upregulated in patients with antibody-mediated rejection [41] , a clinical risk factor for development of allograft vasculopathy. However, future studies will be required to determine if Akt activation is a target for preventing or retarding the development of allograft vasculopathy after organ transplantation.
Complement activation occurs as a result of DSA binding to surface HLA molecules on endothelial cell and is a risk factor for cardiac allograft vasculopathy [42] . Complement activation induces generation of anaphylatoxins C3a and C5a and assembly of membrane attack complexes (MACs) that intercalate into the surface membranes of target cells within graft tissue. Locally produced anaphylatoxins as a result of de-novo synthesis of alternative complement components by endothelial cells [43] signal via G protein-coupled receptors and promote transplant rejection [44] by affecting T-cell activation [45, 46] and suppression [47 && ]. Such activation could promote the development of allograft vasculopathy.
MAC, previously believed to promote inflammation by inducing necrolysis via osmotic diffusion, similarly transmits proinflammatory and prothrombotic signals in target cells. Endothelial cells express high levels of complement regulatory proteins, in particular CD59, which, via cAMPresponse element-binding protein-mediated enhancement of Sp1 transcription factor activity [48 && ], upregulates CD59 surface expression and restricts autologous MAC-induced cell death. In this context, MAC deposition on nucleated cells like endothelial cell induces cellular phenotypes that could promote allograft vasculopathy, including extracellular signal-regulated kinase-mediated [49] and JNK-mediated [50] stress kinase activation, NLRP3 inflammasome activation [51, 52] , and platelet activation [53, 54] . Overall, these studies support the notion that MAC drives pathologic signaling processes in vascular cells that may promote allograft vasculopathy.
By modeling the complement-activating effects of human DSA with 'high' panel reactive antibody sera from allo-sensitized transplant candidates, we identified a novel MAC effector pathway, noncanonical NF-kB, which was required for MAC-treated endothelial cells to upregulate inflammatory genes and potentiate endothelial cell-mediated elaboration of IFNg, a cytokine that promotes allograft vasculopathy, from CD4 þ alloimmune T cells [55] , (Fig. 1) . Endothelial noncanonical NF-kB activation was furthermore detected in human coronary arteries in a humanized mouse model and in patient biopsy specimens with chronic antibody-mediated rejection [56] , a condition strongly associated with allograft vasculopathy. Subsequent studies involving genome wide siRNA screening revealed a novel endosome-based mechanism for MAC to induce noncanonical NF-kB activation. In this mechanism, endocytosis of MAC and the formation of MAC þ Rab5 þ Akt þ vesicles were required for noncanonical NF-kB signal activation [57] . Together, our studies show that noncanonical NF-kB is a MAC effector pathway involved in allograft vasculopathy requiring an endosome-based signaling pathway for its activation.
CONCLUSION
The alarmingly high prevalence and morbidity attributable to allograft vasculopathy underscores a generalized inefficacy of current medical therapies. As discussed above, blockade of HMGB1 in mice reduces allograft vasculopathy [25] . MyD88 inhibition via gene silencing enhanced cardiac allograft survival along with rapamycin treatment [34 & ] but whether this reduced allograft vasculopathy is unknown. Apart from the MyD88 signaling pathway, complement inhibition has also emerged as a putative strategy for blocking allograft vasculopathy lesion formation. Two recent studies targeted endogenous complement regulators CD59 [58 && ] and Crry [59] , a murine complement regulatory ortholog inhibiting C3, using a CR2 fusion protein and single chain antibody, respectively, to relevant sites in vivo in murine hosts to block complement activation in response to IRI. Another recent study used mAb to functionally block proximal activation with anti-C1s [60] . In addition to these antibody-based therapies, pharmacologic agents blocking complement effector pathways like noncanonical NF-kB could be explored as putative strategies for inhibiting allograft vasculopathy. Given the paucity of new therapies to reduce the development of allograft vasculopathy [3] , clinical studies to examine if either inhibition of activators of the MyD88 pathway or the complement activation are safe and effective in reducing allograft vasculopathy should be considered.
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